CORT Stock Overview
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States.
Corcept Therapeutics Incorporated Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$25.64|
|52 Week High||US$29.93|
|52 Week Low||US$15.83|
|1 Month Change||-0.70%|
|3 Month Change||0.79%|
|1 Year Change||29.23%|
|3 Year Change||80.69%|
|5 Year Change||25.87%|
|Change since IPO||109.65%|
Recent News & Updates
Does Corcept Therapeutics (NASDAQ:CORT) Deserve A Spot On Your Watchlist?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
Corcept extends distribution agreement for Cushing’s syndrome drug
Corcept Therapeutics Incorporated (NASDAQ:CORT), the maker of Cushing’s syndrome medication Korlym, has extended its partnership with specialty pharmacy Optime Care, Inc., for U.S. distribution of the treatment. As part of the Sep. 16 amendment to the pharmaceutical manufacturer services agreement, Optime will continue to serve as the exclusive specialty pharmacy dispensing Korlym in the U.S. until Mar. 31, 2024, CORT said in a regulatory filing. In 2017, CORT and Optime entered into a distribution services agreement for the U.S. sales of Korlym, a once-daily oral therapy indicated to treat hyperglycemia secondary to hypercortisolism in certain adults with Cushing’s syndrome. “Korlym is delivering steady sales and earning growth,” and the company is advancing its pipeline with a strong balance sheet, Seeking Alpha contributor Bret Jensen wrote in a recent article on CORT.
Corcept Therapeutics: A Status Check
Summary Today, we put the spotlight on Corcept Therapeutics for the first time in more than a year. The company's Korlym is delivering steady sales and earning growth, the company has a solid balance sheet, and Corcept Therapeutics is also advancing its pipeline. An investment analysis follows in the paragraphs below.
|CORT||US Pharmaceuticals||US Market|
Return vs Industry: CORT exceeded the US Pharmaceuticals industry which returned 5.2% over the past year.
Return vs Market: CORT exceeded the US Market which returned -21.5% over the past year.
|CORT Average Weekly Movement||5.1%|
|Pharmaceuticals Industry Average Movement||11.2%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: CORT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: CORT's weekly volatility (5%) has been stable over the past year.
About the Company
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing’s syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess.
Corcept Therapeutics Incorporated Fundamentals Summary
|CORT fundamental statistics|
Is CORT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CORT income statement (TTM)|
|Cost of Revenue||US$5.20m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||1.05|
|Net Profit Margin||28.75%|
How did CORT perform over the long term?See historical performance and comparison